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Abstract: We studied short- and long-term effects of intravitreal injection of N-methyl-d-aspartate
(NMDA) on melanopsin-containing (m+) and non-melanopsin-containing (Brn3a+) retinal ganglion
cells (RGCs). In adult SD-rats, the left eye received a single intravitreal injection of 5µL of 100nM
NMDA. At 3 and 15 months, retinal thickness was measured in vivo using Spectral Domain-Optical
Coherence Tomography (SD-OCT). Ex vivo analyses were done at 3, 7, or 14 days or 15 months
after damage. Whole-mounted retinas were immunolabelled for brain-specific homeobox/POU
domain protein 3A (Brn3a) and melanopsin (m), the total number of Brn3a+RGCs and m+RGCs
were quantified, and their topography represented. In control retinas, the mean total numbers of
Brn3a+RGCs and m+RGCs were 78,903 ± 3572 and 2358 ± 144 (mean ± SD; n = 10), respectively.
In the NMDA injected retinas, Brn3a+RGCs numbers diminished to 49%, 28%, 24%, and 19%, at 3,
7, 14 days, and 15 months, respectively. There was no further loss between 7 days and 15 months.
The number of immunoidentified m+RGCs decreased significantly at 3 days, recovered between 3
and 7 days, and were back to normal thereafter. OCT measurements revealed a significant thinning
of the left retinas at 3 and 15 months. Intravitreal injections of NMDA induced within a week a rapid
loss of 72% of Brn3a+RGCs, a transient downregulation of melanopsin expression (but not m+RGC
death), and a thinning of the inner retinal layers.
Keywords: NMDA; excitotoxicity; glaucoma; melanopsin-RGCs; intrinsically photosensitive-RGCs;
Brn3a+RGCs; adult albino rat; retina; SD-OCT
1. Introduction
Light is converted by photoreceptors (rods and cones) into electrical signals, which are initially
processed at the outer synaptic layer of the retina where photoreceptor information is modulated by
horizontal cells and conveyed onto bipolar cells. Signals are further processed at the inner synaptic
layer, where the bipolar information is modulated by amacrine cells and finally passed on to retinal
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ganglion cells (RGCs) in the innermost retinal layer. RGCs, the only ones whose axon leaves the
retina, convey the information processed in the retina to the retinorecipient nuclei of the brain.
This projection obtains relevant information from our visual world from the retina and provides
it to the brain to produce image-forming as well as nonimage-forming visual functions. Retinal
information that produces image-forming visual functions is carried out by the general population of
RGCs that have the expression of brain-specific homeobox/POU domain protein 3A (Brn3a) in common,
while the information necessary to produce nonimage-forming visual functions is carried out by a
small subpopulation of RGCs that express the photopigment melanopsin (m+RGCs), rendering them
intrinsically photosensitive (ipRGCs)—the so-called third photoreceptor cell-type of the retina [1].
In adult rodents, RGCs constitute less than 1% of all retinal cells [2–4]. Based on their morphology
(soma size and dendritic arborization), extension of their dentritic arborization into the inner synaptic
layer, electrophysiological responses to light stimulus within their receptive field, target region of the
brain, and genetic background, it has been proposed that the rodent retina may have up to 40 different
types of RGCs [5–8]. In rats it has been estimated that excluding endothelial cells, the ganglion cell layer
is composed of approximately 50% displaced amacrine cells (ACs), 10% glial cells, and 40% RGCs [9].
Displaced ACs not only share their location in the retina with RGCs but overlap in size, thus making
it difficult to distinguish RGCs from ACs, and this has obliged the use of retrogradely transported
neuronal tracers [10,11] or neuronal markers to identify RGCs. There are several markers that identify
large proportions of RGCS (pan-markers) or many RGC types, including Thy-1 [12], Brn3a [13,14],
RBPMS [15], class III beta-tubulin [16], Neuronal Nuclei (NeuN) [17], and Microtubule-associated
protein 1A (MAP 1A) [7,18]. In addition, there are several markers that allow identification of
specific types of RGCs, such as melanopsin [19] and others [7,8,20]. However, after retinal injury,
many of the physiological and morphological attributes of RGCs, including their dendritic arborization,
may change [8,21,22], and the molecular markers may be downregulated, rendering the identification
of RGCs difficult [23–28].
The characterization of the expression of Brn3a by rodent RGCs has allowed identification of the
main population of RGCs that convey image-forming visual information to the brain, which represents
approximately 96% of the RGC population [14]. Nonimage-forming visual behaviours depend on
intrinsically photosensitive RGCs (ipRGCs), one type of RGC with a large dendritic arbor that contains
the photopigment melanopsin (m+RGCs), which is responsible for the circadian photoentrainment,
pupillary reflexes, and the regulation of pineal melatonin secretion [1,29,30]. Six subtypes of ipRGCs
have been described to express at least small amounts of melanopsin (also known as Opn4), and are
named M1-M6 [31,32]. Antibodies against melanopsin allow the identification of the large majority of
ipRGCs, preferentially M1–M3, because M4 (which corresponds to the ON αRGC subtype [33,34]),
M5 [35], and M6 [32] express less Opn4 than M1–M3 and are difficult to identify with standard
immunohistochemistry [31,32,36–40]. In rats, the population of m+RGCs constitute approximately
2.5 and 2.7% of the pigmented and albino RGC populations, respectively [13,14,19,41,42]. Moreover,
because Brn3a and melanopsin are rarely expressed in the same RGC, immunohistofluorescent studies
using these two markers together allows the study, in parallel but independently, of the responses of
these two types of RGCs to different retinal injuries [28,43].
Glutamate excitotoxicity may be induced by the intravitreal injection of N-methyl d-Aspartate
(NMDA), which results in the excessive stimulation of NMDA receptors, one of the three ionotropic
glutamate receptor subtypes widely expressed by inner retinal neurons. Glutamate excitotoxicity is
thought to play an important role in the loss of RGCs in various retinal injuries [44,45], including
glaucoma [46–50], transient ischemia [51], and optic nerve injury [52,53], and may also play a key
role in many CNS diseases involving neuronal death [54]. Excessive NMDA receptor stimulation
may result in alterations of the Na+/K+ homeostasis, excessive influx of large amounts of Ca2+ into
the cell [55], which may result in direct damage by activation of enzymes that damage DNA and cell
membranes [56] and by the induction of apoptosis through activation of c-AMP [57]. Animal models
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of NMDA-induced retinal excitotoxicity are often used to explore molecular mechanisms of RGC
apoptosis and its protection [58–66].
The susceptibility of RGCs to NMDA-mediated excitotoxicity has been studied previously in
adult rats [58,62] and mice [59,67], as well as the effects of intravitreal NMDA on the specific type
population of m+RGCs [59,67]. However, these were short term studies spanning up to 58 days after
NMDA injection, and thus the short- and long-term effects of NMDA excitotoxicity on the population
of RGCs expressing Brn3a have not been investigated so far. Moreover, to what extent NMDA-induced
neurotoxicity may result in long term effects on the retinal architecture and on the population of
ipRGCs itself have not been previously investigated.
In the present study we take advantage of recent techniques developed in the laboratory to
identify, count, and map in the same retinal wholemounts the populations of RGCs expressing Brn3a
or melanopsin. Moreover, we use modern non-invasive techniques, such as the Spectral Domain
Optical Coherence Tomography (SD-OCT), to image and analyze retinal thickness longitudinally at
short (3 months) and long (15 months) survival intervals. We investigate the responses of the general
population of RGCs (Brn3a+) and the population of ipRGCs (m+RGCs) to excitotoxicity induced
by the intravitreal injection of NMDA. Overall, our studies indicate that the general population of
Brn3a+RGCs is quite sensitive to NMDA-mediated excitotoxicity, which in one week induces the loss
of approximately 72% of the population. In contrast, m+RGCs, after a transient downregulation of
melanopsin, show a remarkable capacity for survival of the entire m+RGC population for periods of up
to 15 months. Examination of these retinas with SD-OCT reveals that NMDA-injected retinas showed
a marked reduction in the thickness of the total and inner retina that was present at 3 months and
progressed up to 15 months. Short accounts of this work have been published in abstract format [68].
2. Results
We have included in this study a total of 51 rats whose left eye received an intraocular injection of
5 µL NMDA (100 nM). The first 28 were analyzed within the first 14 days after the injection while the
remaining 23 were analyzed at 15 months to investigate the long-term effects of the excitotoxic insult
on the survival of two RGC populations—the Brn3a+RGCs and the m+RGCs. Five additional naïve
rats were used as controls. In addition, SD-OCT was used to measure retinal thickness in both retinas
of 18 animals at 3 and 15 months after NMDA injection.
2.1. Rapid and Massive Loss of Brn3a+RGCs Shortly after NMDA Injection
When the right or naïve retinas were examined under a fluorescence microscope, Brn3a+RGCs
showed typical distribution throughout the entire retina with higher densities on the superior retina,
just above the optic nerve along the visual streak, as described in detail previously [69–71]. Changing
the fluorescent filter allowed us to see m+RGCs distributed in a complementary fashion to Brn3a+RGCs,
and as previously shown by this laboratory [14,19], we were not able to see any doubly immunolabelled
RGC, thus confirming that these markers are exclusive to one population (Figure 1).
Total numbers of Brn3a+RGCs (78,903 ± 3573 mean ± SD, n = 10) in the naïve retinas were
comparable to those in the right fellow retinas of our experimental groups analyzed at 3, 7, and 14 days
(76,472 ± 5815 Brn3a+RGCs mean ± SD, n = 29), or 15 months (81,480 ± 5602 mean ± SD, n = 20) after
NMDA injection, as well as to those obtained in previous studies from this laboratory [13,14,19,72]
(Figures 1 and 2, Table 1).
The left NMDA-injected retinas showed significant decreases in the total numbers of Brn3a+RGCs.
By 3 days after NMDA injection, the total number of Brn3a+RGCs was 38,940 ± 22,443 (n = 9), which is
significantly smaller than naïve controls and contralateral retinas (Mann Whitney test, p ≤ 0.001).
There were further reductions at 7 (21,811 ± 9750 mean ± SD, n = 6) and 14 days (19,348 ± 8502 mean ±
SD, n = 10) but these were not statistically significant when compared to 3 days, indicating that in
this injury model RGC loss occurs early after NMDA injection, but there is no further progression
between 3 and 14 days (Figure 2, Table 1). Moreover, at 15 months, the left NMDA-injected retinas
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showed significantly lower numbers than their fellow retinas (15,099 ± 8595 mean ± SD, n = 23) that
corresponded to a survival of approximately 19%, and these values were significantly smaller than
those observed at 3 days (Mann Whitney test, p = 0.019), but not from those obtained at 7 days (Mann
Whitney test, p = 0.187), indicating that there is no further loss of Brn3a+RGCs between 7 days and 15
months (Figures 1–3, Table 1).
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Figure 1. Magnifications from flat mounted retinas showing brain-specific homeobox/POU domain 
protein 3A positive retinal ganglion cells Brn3a+RGCs (A,B) and melanopsin positive retinal ganglion 
cells m+RGCs (A’,B’), and both signals (merge) (A’’,B’’) in contralateral (A,A’’) and N-methyl-D-aspartate 
(NMDA)-treated retinas (B,B’’) analyzed at 15 months after the injection. Brn3a labels cell nuclei, while 
melanopsin allows one to see cell somata as well as primary dendrites on the plane of focus. When both 
images are overlapped (A’’, B’’), one can appreciate the smaller density of m+RGCs compared to 
Brn3a+RGCs, as well as the fact that there are no doubly labelled RGCs. Note that 15 months after NMDA 
injection there are fewer Brn3a+RGCs. Scale bar = 50 µm. 
Figure 1. Magnifications from flat mounted retinas showing brain-specific homeobox/POU domain
protein 3A positive retinal ganglion cells Brn3a+RGCs (A,B) and melanopsin positive retinal ganglion
cells m+RGCs (A’,B’), and both signals (merge) (A”,B”) in contralateral (A,A”) andN-methyl-d-aspartate
(NMDA)-treated retinas (B,B”) analyzed at 15 months after the injection. Brn3a labels cell nuclei,
while melanopsin allows one to see cell somata as well as primary dendrites on the plane of focus.
When both images are overlapped (A”,B”), one can appreciate the smaller density of m+RGCs compared
to Brn3a+RGCs, as well as the fact that there are no doubly labelled RGCs. Note that 15 months after
NMDA injection there are fewer Brn3a+RGCs. Scale bar = 50 µm.
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at 3, 7, 14 days, or 15 months. When compared with the previous time study interval (at 7 days, 14 days, 
or 15 months), there were no significant differences (Kruskal-Wallis test, p > 0.05). However, there were 
significant differences between 3 days and 15 months (# Mann Whitney test, p = 0.019), but not from those 
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representative retinas analyzed at 3 (B), 7 (C), 14 (D) days, or 15 (E) months after intravitreal injection of 
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Figure 2. ar gra h showing the percent vs. intact retinas of the total numbers of Brn3a+RGCs ±
standard deviation quantified in the contralateral uninjured and experimental retinas analyzed 3, 7,
14 days, or 15 months after the intraocular injection of 100 nM NMDA. The number of Brn3a+RGCs in
the intact naïve retinas was considered 100%. The number of analyzed retinas is shown at the bottom
of each bar. Statistically significant differences were observed (Kruskal-Wallis test, p < 0.001) between
values obtained in intact retinas (naïve) or right eye retinas (contralateral) and experimental retinas
examined at 3, 7, 14 days, or 15 months. When compared with the previous time study interval (at
7 days, 14 days, or 15 months), there were no significant differences (Kruskal-Wallis test, p > 0.05).
However, there were significant differences between 3 days and 15 months (# Mann Whitney test,
p = 0.019), but not from those obtained at 7 days (Mann Whitney test, p = 0.187), which suggests that
NMDA-induced Brn3a+RGC loss does not progress between 7 days and 15 months.
Table 1. Total numbers of Brn3a+RGCs in right (RE) or left (LE) eye retinas.
Retinas
Naïve 3 Days 7 Days 14 Days 15 Months
RE LE RE LE RE LE RE LE RE LE
1 80,293 82,587 72,071 46,569 74,963 24,880 71,159 16,434 89,717 14,852
2 80,399 79,044 79,209 52,957 77,604 12,227 80,940 13,785 93,939 9538
3 78,344 71,826 78,178 72,411 33,105 78,786 10,593 88,081 24,936
4 74,865 77,395 79,256 19,910 66,564 73,895 39,166 81,353 21,955
5 84,031 80,247 82,406 15,648 66,086 31,097 77,579 16,132 78,436 22,369
6 74,244 15,721 63,952 9238 82,321 68,961 1951
7 62,993 71,202 20,321 87,289 15,318 83,471 5796
8 62,344 80,773 22,261 80,699 21,478
9 61,640 84,397 20,945 16,245
10 12,681 80,789 12,209 24,937
11 76,135 26,641 74,808 16,594
12 88,721 8588
13 75,941 1990
14 2754
15 80,213 10,950
16 81,595 5404
17 80,424 5584
18 79,487 25,879
19 79,093 25,486
20 77,667 21,966
21 81,417 11,286
22 83,543 25,152
23 82,032 21,587
Mean 78,903 77,561 38,940 70,397 21,811 79,460 19,348 81,480 15,099
± SD 3572 3757 22,443 5038 9751 4631 8502 5602 8595
Total RE Mean 78,677 SD 6260
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Figure 3. (A–E) Isoden ity maps showing th tinal topography of Brn3a+RGCs in intact etinas (A) or
in representative retinas analyzed at 3 (B), 7 (C), 14 (D) days, or 15 (E) months after intravitreal injection
of 100 nM NMDA. (A’–E’) Neighbor maps illustrating the distribution of m+RGCs in the same retinas
shown in (A–E). Isodensity maps color scale ranges from 0 (purple) to ≥ 2500 (red) cells/mm2. Neighbor
map color scale, where each color represents an increase of 4 neighbors in a radius of 0.22 mm from
purple (0–4 neighbors) to dark red (32–35 neighbors). Below each map is shown the total number of
Brn3a+RGCs or m+RGCs counted. Note: S = superior; I = inferior; N = nasal; T = temporal. Scale bar
= 1 mm.
Retinal distribution of Brn3a+RGCs in the NMDA-injected retinas did not adopt any particular
spatial pattern; their loss was diffuse and distributed over the entire amount of retinas (Figure 3),
although occasionally there was a smaller density in the superior temporal quadrant that could be
explained by the proximity to the intraocular puncture, and thus, a region exposed to a greater
concentration of the injected NMDA.
2.2. After A Transient Downregulation of Melanopsin, m+RGCs Appear Fully Resistant to NMDA Injection
Total numbers of m+RGCs (2358 ± 143 mean ± SD, n = 10) in the naïve retinas were comparable
to those obtained in the right fellow retinas of our experimental groups analyzed at 3, 7, and 14 days
(2257 ± 228 m+RGCs mean ± SD, n = 29), or at 15 months (2166 ± 96 mean ± SD, n = 9) after NMDA
injection, as well as to those obtained in previous studies from this laboratory [13,19,69] (Figures 1, 3
and 4, Table 2).
By 3 days after intravitreal injection of NMDA, the total number of m+RGCs was 1516 ± 312
(n = 10), a significant reduction when compared to naïve or contralateral retinas (Kruskal Wallis test,
p ≤ 0.001) (Figure 2). Surprisingly, the total number of m+RGCs at 7 or 14 days after NMDA injection
was 2105 ± 445 (n = 7) or 2419 ± 257 (n = 11), showing a significant increase when compared to the
values observed at 3 days, and reached comparable values to those of control retinas by 14 days
(Kruskal Wallis test, p > 0.05). By 15 months after NMDA injection, the left retinas showed a total
number of m+RGCs (2027 ± 134 mean ± SD, n = 11) comparable with the data obtained in their right
fellow retinas (2166 ± 96 mean ± SD, n = 9) (Mann Whitney test, p = 0.518).
We interpret this abrupt decrease and subsequent recovery of the total number of m+RGCs as a
transient downregulation of melanopsin, shortly after intravitreal injection of NMDA, which recovers
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up to normal levels of expression and total number of m+RGCs by 7 days, 14 days, and 15 months.
In addition, these results also indicate that m+RGCs are resistant to NMDA-induced excitotoxicity.
In contrast with the Brn3a+RGC population, whose total numbers were reduced to approximately one
quarter to one fifth of their normal values, the m+RGCs show a complete population that is comparable
to that found in their fellow contralateral and in naïve retinas (Figures 1, 3 and 4, Table 2).
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Figure 4. Bar graph showing the percent vs. intact retinas of the total number of m+RGCs ± standard
deviation quantified in the contral ter l uninjured and experimental reti s analyzed 3, 7, 14 days,
or 15 months after the intr i jection of 1 0 nM NMDA. The number of analyzed retinas is shown
at the bottom f each bar. Note: * Signifi ifferences compared to naïve, contral teral reti as, and
other time points (Kruskal-Wallis test, p < 0.001); the percent of m+RGCs in the experimental groups
analyzed at 7 days, 14 days, or 15 months did not differ significantly from their contralateral fellow
retinas (Mann-Whitney Test, p > 0.05).
Table 2. Total numbers of m+ s in right (RE) or left (LE) eye retinas.
Retinas
Naive 3 Days 7 Days 14 Days 15 Months
RE LE RE LE RE LE RE RE LE
1 2434 2201 2135 2062 2163 1678 2034 2409 1994
2 2373 2445 1972 1293 2496 1650 2026 2018
3 2366 2103 2294 1187 1962 1860 2055 2154 1997
4 2362 2249 2547 1682 2262 1971 2242 2425 2297 1987
5 2612 2433 1966 1043 2040 2174 2566 2585 2207 1904
6 2183 1448 2471 2662 2363 2145 2016 1857
7 1719 2612 2746 1950 2661 2267 2019
8 1473 2537 2701 2022 2284
9 1850 2267 1955 2156 1961
10 1411 2559 2660 2196 2004
11 2467 52 2181 2273
Mean 2358 2183 1453 2287 2106 2279 2420 2166 2027
± SD 144 219 371 247 446 235 257 95 133
Total RE Mean 2257 SD 229
2.3. In Vivo SD-OCT Measurements
We wanted to examine the effects of the NMDA-induced retinal degeneration on the retinal layers,
and thus retinas were analyz d at 3 and 15 months with SD-OCT to determine the total and inner
retinal thickness. Figur 5 shows representative SD-OCT images from both eyes in two representative
experimental rats analyzed longitudinall in vivo 3- and 15-months after NMDA-injection. The SD-OCT
provided measurements of the 31 sections acquired, and we selected three sections located superior,
central, or inferior for analysis. Because the measurements of these three sections were comparable
within each individual retina and time interval examined, the values from these 3 sections were pooled
and used as a value for each retina and time point.
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Fig re 5. I vivo Spectral o ai - tical o ere ce o ogra y (S - ) i ages fro t e sa e co tralateral a ex eri e tal reti as a alyze 3 a 15 o t s
after injection. ( , , ) e resentative i ages of the oc lar f n s of the contralateral retina an osition of the 31 sections acq ire . he s erior ( ),
central ( ), or inferior ( ) retinal sections are arked in red. (B, ,E,F, ,I) Representative sections acquired (in red) fro S - T volu e raster scan in contralateral
(B,E, ) and -injected (C,F,I) retinas exa ined longitudinally at 3- onths (B–I) and at 15- onths (B’–I’) after DA injection.
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Total retinal (TR) thickness (as measured in µm from the inner side of the nerve fiber layer to
the outer limit of the outer segment layer) was significantly smaller in the NMDA-injected retinas as
compared to their contralateral fellow retinas at 3 months (185 ± 4 versus 211 ± 3.9; n = 18) and 15 (162
± 6.1 versus 195 ± 6.1; n = 18) months. In fact, the thinning of the TR was mainly due to the thinning of
the inner retina (IR) (as measured in µm from the inner side of the nerve fiber layer to the outer limit of
the inner nuclear layer). The IR thickness in the left NMDA-injected eyes was significantly smaller
than in their fellow retinas at 3 months (83 ± 3.7 versus 96 ± 2.6; n = 18) and 15 (71 ± 2.8 versus 91 ±
3.4; n = 18) months (Figures 5 and 6).
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Figure 6. Graph bars showing the reduction of the mean ± SD thickness (µm) of the total (from
inner side of the nerve fiber layer to outer segment layer) and inner (from the inner side of the nerve
fiber layer to outer margin of inner nuclear layer) retina after NMDA intravireal injection into the
left eye, measured in the volume scan analyses shown in Figure 5. Note: * Significant differences
compared to the same eyes analyzed at 3 months (Kruskal-Wallis test, p < 0.001); # significant differences
when compared to their contralateral eyes at the same time interval (Mann-Whitney Test, p < 0.001);
RE = right fellow eye; LE = left eye (NMDA-injected).
The TR thickness of the fellow retinas diminished significantly between 3 (211 ± 3.2; n = 18)
and 15 (195 ± 6.1; n = 18) months, a finding that is in agreeme t with rec t studies in adult albino
rats showing a physiol gical thi ni of the TR nd IR of approximately 16 and 6 µm, respectively,
with age [69]. H wever, superimposed to the physiological age-related thinning of th retina, in the
experimental NMDA-injected retinas there was further significan thinni g of the TR (23 µm) and IR
(12 µm) between 3 and 15 months (Figures 5 nd 6).
3. Discussion
Here we have investigated the short- and long-term responses of the populations of Brn3a+ and
melanopsin expressing (m+) RGCs after a excitotoxic insult to the retina. Our studies show that
following an intraocular injection of 100 nM NMDA, there is a rapid and massive loss of the general
population of Brn3a+RGCs; by 3 days, 14 days, or 15 months, the surviving population represents
approximately 49%, 24%, or 19%, respectively, of the riginal populatio . When examined with
SD-OCT there was an important reduction in the thickness of the total and the in er retina at 3 months
that further progressed up to 15 months.
Compared to the po ulation of Brn3a+RGCs, m+RGCs show by 3 days a transient downregulation
of melanopsin that recovers over the next weeks, and by 14 days or 15 months the numbers of m+RGCs
are comparable t their contralateral fellow eyes.
When studying the res onses of RGCs to retinal injuries it is important to be able to identify
different types of RGCs to understand how these respond to injury [43,73]. Here, we use modern
techniques develope in the laboratory to cou t, image, and represent the retinal topography of two
RGC populations that can be readily identified with Brn3a and melanopsin [43,74]. Recent studies from
this laboratory have demonstrated that in the adult rat, retinal injuries induce a transient downregulation
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of melanopsin [28], followed by the expression of melanopsin in injured neurons surviving long periods
of time [9,19,75,76]. Of the six main subtypes of ipRGCs M1–M6, immunocytochemistry against
melanopsin identifies mainly M1–M3 because they show higher levels of melanopsin expression [32–35,
37,38], and thus when interpreting our data, we should take into account that our immunohistochemical
methods primarily identify the M1–M3 ipRGC subtypes. In fact, although not analyzed in this work,
it is conceivable that most of our results refer to the M1 and M2 subtypes, which are the most abundant
and readily identified with melanopsin antibodies [37,38,40,77].
3.1. Intravitreal Injection of NMDA Induces Brn3a+RGC Death
The loss of RGCs observed after the injection of NMDA in our studies is comparable to that
found by others in mice [59,67] or rats [53,58,78] analyzed at survival intervals ranging 3–58 days.
We noticed certain inter-animal variability in the total number of surviving Brn3a+RGCs at 3 days
after NMDA injection, which was also reported by others [58,67] and could be due to an individual
animal susceptibility, or to the fact that RGC loss has not concluded by that time interval. Inter-animal
variability following other types of retinal injuries, such as intraorbital optic nerve cut or crush, an insult
that results in axotomy of the entire RGC population, have been shown [9,79]. Another possible
explanation for the inter-animal variability could be the fact that intravitreal injections may suffer a
small reflux of the injected volume rendering the concentration of NMDA unequal for all eyes. We have
not investigated shorter survival intervals than 3-days after NMDA injection, but other studies have
suggested that following NMDA injection RGC loss appears as early as 6-h after injection [80]. It is
currently thought that NMDA-induced excitotoxicity results in activation of the NMDA receptor and
this leads to a massive influx of Ca++ that acts as a second messenger to activate pathways that lead to
apoptotic neuronal death [81], although the exact signalling pathways involved in NMDA-induced
RGC death are not completely understood [61].
By 14 days, approximately 75% of the original Brn3a+RGC population has degenerated.
Their topography does not reveal any particular distribution, such as the patchy or sectorial patterns
observed after acute or chronic ocular hypertension, respectively [82–84], but rather a diffuse pattern of
RGC loss much like the pattern observed after crushing or cutting of the intraorbital optic nerve [70,74].
In some instances, over the general diffuse pattern of RGC loss, there was a marked decrease in the
superior temporal quadrant, the region where NMDA was injected, and thus where NMDA may have
reached a higher concentration.
Our results indicate that RGC loss is not progressive, since between 7-days and 15-months
after NMDA injection there are no significant changes in total numbers of Brn3a+RGCs. Our results
appear in disagreement with those of Huang and colleagues [78] that reported a progressive RGC loss
between 12 h and 58 days, but these authors employed Neu-N antibodies as a marker to identify RGCs,
which identify displaced amacrine cells in addition to RGCs [17], and RGC densities were obtained
by averaging 16 samples obtained throughout the retina, whereas our numbers were obtained after
counting the entire amount of retinas. Nevertheless, Huang and colleagues [78] reported the loss of
approximately 67% of the RGC population at 58 days, which is analogous to the 75% loss observed in
our studies.
3.2. Intravitreal Injection of NMDA Induces A Progressive Retinal Thinning
RGC degeneration results in the loss of neural processes that extend into the inner synaptic layer,
where they contact cone-bipolar and amacrine cells of different types forming an extensive neuropil
that makes up a substantial proportion of the inner synaptic layer’s volume. Our results indicate
that NMDA-induced retinal excitotoxicity results in a significant decrease of the total (TR) and inner
(IR) retinal thickness. This thinning was already apparent in the left NMDA-injected experimental
retinas at 3 months when compared to their fellow retinas. The retinal thinning may be explained
because over 75% of the Brn3a+RGC population is missing and their dendrites have degenerated,
thus prompting a thinning of the IPL [78], but also because NMDA-excitotoxiticy results in loss of
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amacrine cells, as shown with Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
and morphometric techniques in adult pigmented mice [85–87] and albino rats [78,88]. The thinning
of the TR and IR observed in the fellow retinas between 3 and 15 months is consistent with the
physiological thinning of the adult SD rat retina with age [72]. However, superimposed on this
physiological thinning, in the experimental retinas there was a progressive thinning of the TR and IR
between 3 and 15 months, indicating a continuing retinal degeneration prolonged beyond the time
of NMDA injection and the period of Brn3a+RGC loss, which concluded at 7 days after the injection.
A possible explanation for the progressive thinning of the IR could be the secondary amacrine cell loss
that follows RGC death observed after NMDA-induced neurotoxicity. Indeed, approximately 72% of
the RGC types in the mice retina are coupled to ACs [89], which may possibly facilitate secondary cell
loss of calretinin, calbindin, and choline acetyltransferase immunopositive ACs via gap junctions [87].
3.3. The m+RGCs Resilience to Retinal Disease and Injury
In the adult rat, m+RGCs only represent approximately 2.7% or 2.5% of the total population of
RGCS in albino or pigmented populations, respectively [14,19,72]. Yet, the availability of specific
molecular markers for this type of RGCs has made it possible to learn in a very short period of time
a great deal about the morphological and functional properties of these neurons, including their
idiosyncratic response to different types of inherited or acquired retinal lesions [43]. A number of
different laboratories have shown that ipRGCs demonstrate a much better survival against a variety
of retinal injuries than the general population of RGCs [90], and this particular resilience has been
shown against ocular hypertension in rats [39,91] or mice [92], crushing or cutting of the optic nerve in
rats [93,94] or mice [35,76,95,96], and transient ischemia of the retina in rats [84]. However, ipRGCs do
not appear to be particularly resilient in inherited models of retinal degeneration [95–99], mitochondrial
optic neuropathies [100], or degenerative diseases [77], such as Alzheimer’s [101], Parkinson’s [102],
or Huntington’s [103] disease. A detailed characterization of the RGC responses to NMDA-induced
excitotoxicity may shed light into the paradigm of the different responses of different populations of
RGCs to injury; why some populations die while others survive.
3.4. The m+RGCs Are Resistant to NMDA-Induced Retinal Excitotoxicity
Our results demonstrate that following a transient downregulation of melanopsin expression,
the total number of m+RGCs at 14 days or 15 months is comparable to their contralateral fellow eyes,
thus indicating an outstanding endurance to NMDA-induced excitotoxicity.
Survival of the entire m+RGC population at 15-months after NMDA injection is underscored in
view of the important inner retinal degeneration and loss of approximately 81% of the Brn3a+RGC
population. The degeneration of RGCs following NMDA-induced excitotoxicity has been explored in
adult pigmented mice analyzed at 6 [67] or from 1 to 21 [59] days, respectively. However, these studies
showed slight differences in terms of the survival of the m+RGC population. DeParis and colleagues [67]
found that 6 days after NMDA injection there was a full component of m+RGC population surviving
in the retina with no downregulation of the expression of melanopsin, while Wang and colleagues [59]
reported the loss of approximately one half of the m+RGC population at 21-days after NMDA injection.
These differences may be explained by the diverse amount of NMDA injected (3 µL of 10 mM NMDA
versus 1 µL of 40 mM NMDA).
The downregulation of melanopsin expression that occurs after retinal injury requires further
consideration. Our studies reveal that following NMDA injection there is a transient downregulation
of melanopsin that recovers fully by 14 days. A similar transient downregulation of melanopsin has
been described in previous studies from this laboratory in adult rats following optic nerve injury [94],
transient elevation of the intraocular pressure [84], the use of retrogradely transported neuronal
tracers [104], or acute light-induced retinal degeneration [75]. The differences between our results and
those observed by DeParis and colleagues [67] may be a species-specific response of m+RGCs, because
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in parallel studies of m+RGC survival in adult mice following intraorbital optic nerve injury, we did
not find a transient downregulation of melanopsin [28,76].
Of all the retinal injuries examined so far, m+RGCs best tolerate NMDA-induced excitotoxicity.
The reasons for the remarkable resilience of ipRGCs to survive different types of injury-induced retinal
degeneration remains an open issue for future studies, but several hypotheses have been forwarded
to explain m+RGC resilience. One hypothesis proposes that these ipRGCs have large dendrites
within the inner synaptic layer, and thus their intra-retinal connections may be enough to provide
trophic support for survival in the absence of brain-target-derived trophic support [29,90,93,105].
Although it has been postulated that the absence of NMDA receptors in m+RGCs could explain
their particular resistance to NMDA-mediated excitotoxicity, it has been shown that all RGCs express
NMDA receptors [106], including m+RGCs [66,107], and that the particular resilience of m+RGCs is
not related to pigmentation, genetic background, the presence of photoreceptors, or the activation of
the endogenous survival JAK/STAT pathway [67]. Other possible explanations include the activation
of the PI3K/AKT pathway after cutting of the optic nerve or ocular hypertension [108], but this
was not apparent in NMDA-induced excitotoxicity [67]. Melanopsin itself could be thought to
have an effect on cell survival, but the fact that many ipRGCs survive with a transient, but lower,
expression of melanopsin makes this unlikely. Another hypothesis explains the resilience on the basis
of their neurotransmitter (PACAP) and it is hypothesized that PACAP would act as a neuroprotectant
conferring these neurons their particular resistance, since exogenous administration of PACAP protects
RGCs against optic nerve transection [109], ocular hypertension [110], or NMDA administration [111].
It could also be possible that different types of RGCs may have different responses to the same insult,
thus arguing in favour of a type-specific susceptibility. For example, recent studies using genetic
markers to identify different types of RGCs have shown that the type of αRGC is particularly resistant
to NMDA induced neurotoxicity [8] or to optic nerve crush [35,39], in contrast to the very low survival
of junction adhesion molecules B-expressing RGCs (J-RGCs) [8]. Moreover, recent studies indicate that
different subtypes of ipRGCs have different susceptibility to specific insults; for instance, in a mouse
model of Huntington’s disease (HD), M1 were reduced compared to non-M1 ipRGCs that survived to
HD progression [112]. Furthermore, in a mouse model of ocular hypertension, subtypes of αRGCs
were found to have different susceptibility, with OFF-transient αRGCs being more vulnerable than
ON- or OFF-sustained αRGCs [22,73]. Overall, the particular resilience of m+RGCs makes them a
suitable candidate to study changes in protein expression after injury, which furthers our knowledge
about what makes a neuron survive better than others, and this could in turn result in the design of
new neuroprotective strategies for RGCs against noxious stimuli. Thus, future studies are needed
to decipher the molecular correlations that provide these neurons with a self-built neuroprotection
against various types of injury, including NMDA-induced RGC death.
4. Material and Methods
4.1. Animal Handling and Experimental Groups
Experiments were prepared in 56 adult female SD rats (250 g) obtained from the animal house
(Murcia University, Murcia, Spain) and treated according to the European Union guidelines for Animal
Care and use of scientific purpose (Directive 2010/63/UE). All procedures were approved by the Ethical
and Animal Studies Committee of the University of Murcia, Spain (Comité Ético de Experimentación
Animal (CEEA) de la Universidad de Murcia, 11 January 2017, Code: A13170110 and A13170111).
Animals had free access to food and water and were kept in a temperature and light controlled room
with 12-h/12-h light/dark cycles. Animals were anaesthetized with a mixture of xylazine (10 mg/kg
Rompun; Bayer, Kiel, Germany) and ketamine (60 mg/Kg bw, Ketolar; Pfizer, Alcobendas, Madrid,
Spain); 0.5% proparacaine hydrochloride eye drops (Alcon Co., Fort Worth, TX, USA) were used to
achieve topical anaesthesia. After the surgical procedures, an ocular ointment was placed over the
corneas of both eyes to prevent corneal desiccation (Tobrex®; Alcon-Cusí, S.A., Barcelona, Spain).
Int. J. Mol. Sci. 2019, 20, 3012 13 of 21
Animals were divided into experimental and control groups. The experimental group received an
intraocular injection of NMDA and was divided into four subgroups that were examined at 3 (n = 10),
7 (n = 7), or 14 (n = 11) days, or 15 months (n = 23). Additional naïve rats (n = 5) were used as controls.
For animal sacrifice an overdose of sodium pentobarbital was injected intraperitoneally (Dolethal,
Vetoquinol®, Especialidades Veterinarias, S.A., Madrid, Spain).
4.2. Intraocular Injections of NMDA
Retinal excitotoxicity was induced in the left eye of the experimental animals by intraocular
injection of 5 µL of 100nM NMDA N-methyl-d-Aspartate (NMDA) (M3262; Sigma-Aldrich Química
S.A., Madrid, Spain) dissolved in 0.1 M phosphate buffer saline (PBS) following standard techniques in
our laboratory [113–115]. In brief, a small puncture in the sclera approximately 1 mm from the limbus
was made with a 30-gauge needle, and then NMDA was injected slowly with a Hamilton syringe
whose needle was introduced through the sclerotomy. After injection, the needle was withdrawn
slowly and an ointment (Tobrex pomada; Alcon S.A., Barcelona, Spain) was placed over the eyes to
prevent corneal dehydration until anaesthesia recovery. The contralateral non-injected eye was used as
control, and 5 naïve rats (10 eyes) were also used as controls. Preliminary experiments allowed us
to try increasing doses of NMDA to find one that would result in consistent RGC death. Previous
studies from this Laboratory did not find any effect of the intraocular injection of vehicle alone (0.1 M
phosphate buffer saline, PBS) on the survival of the Brn3a+ or melanopsin+ RGC populations, and thus,
we did not employ additional animals for this purpose.
4.3. In Vivo Measurements of the Retinal Thickness with SD-OCT
SD-OCT measurements were obtained to analyze changes in the thickness of the retina following
NMDA intraocular injection, and the eyes were imaged at 3 and 15 months, as previously described
in detail [72,116]. Rats were anaesthetized systemically, and eye drops were placed on both eyes to
induce mydriasis (Tropicamida 1%; Alcon-Cusí, S.A.) and to prevent corneal desiccation (artificial
tears). Rats were placed in prone position over a platform with their heads upright and turned to the
opposite side of the inspected eye. The head position was kept similar for all animals, and for the
following examination the follow up tool of the OCT program was used to compare the same regions.
Both retinas were examined with OCT following manufacturer guidelines (Spectralis; Heidelberg
Engineering, Heidelberg, Germany). To compensate for the rat’s corneal curvature and to maintain its
hydration, we placed over the cornea a customized permeable contact lens (3.5-mm posterior radius
of curvature, 5.0-mm optical zone diameter, 5.0-diopter back vertex power). To observe the rat’s eye
fundus we placed in front of the camera a commercially available 78-diopter double aspheric lens
(Volk Optical, Inc., Mentor, OH, USA). Photographs were taken with a software package (EyeExplorer,
version 3.2.1.0; Heidelberg Engineering). Retinal thickness was determined with a raster scan of 31
equally spaced horizontal B-scans (3000 µm length) centred on the optic nerve head. For each section
total retinal (TR) (as measured from the inner limiting membrane to the outer limit of the pigmented
epithelial layer) and inner retinal (IR) (as measured from the inner limiting membrane to the outer limit
of the inner nuclear layer) thickness were measured at distances of 1800 µm from optic disc. A total of
18 rats were analyzed longitudinally at 3 and 15 months.
4.4. Retinal Dissection, Immunohistochemistry and Image Acquisition
At different survival intervals, rats were sacrificed and perfused through the heart, first and briefly
with a solution of 0.9% NaCl, and then slowly with a 4% paraformaldehyde solution in PBS. The superior
pole of the eye was marked with a small suture, and retinas were then dissected and prepared
as flattened wholemounts, as previously described [117]. Retinas were double-immunodetected
following previously described methods for Brn3a and melanopsin to identify surviving RGCs
expressing these two markers [14]. Primary antibodies were goat anti-Brn3a (1:750 dilution, C-20 Santa
Cruz Biothechology, Heidelberg, Germany) and rabbit anti melanopsin (1:500 dilution, PAI-780,
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Invitrogen, Thermo Fisher Scientific, Alcobendas, Madrid, Spain). Secondary antibodies were Alexa
Fluor conjugated (donkey anti-rabbit Alexa 594, donkey anti-goat Alexa 488) (Molecular Probes
Thermo-Fisher, Madrid, Spain). At the end of the immunohistochemical procedure, both retinas were
mounted (vitreal side up) on gelatinized slides with an antifading solution [14].
Using epifluorescence microscopy (Axioscop 2 Plus; Zeiss Mikroscopie, Jena, Germany) retinas
were photographed according to standard methods in the laboratory [76,118]. A total of 154 frames were
obtained in the microscope to reconstruct the whole retina. These reconstructions were obtained under
both filters to allow identification of Brna3a+RGCs and m+RGCs, respectively. Following standard
procedures in the laboratory [74,119,120], wholemount reconstructions were further processed to
automatically obtain the total number of Brn3a+RGCs and their topographical distribution was
represented as isodensity maps. For the m+RGCs, these were quantified manually and dotted on the
photomontage with the aid of a graphic editing software Adobe Photoshop CS8.01 (Adobe Systems,
Inc., San Jose, CA, USA). Dots were automatically identified, and their topographical distribution was
represented as neighbour maps following previously described methods [120].
4.5. Statistics
All data is expressed as means ± standard deviation (SD). Statistical analysis employed the
program GraphPad Prism® for Windows (Version 5.01; GraphPad Software Inc., La Jolla, CA, EEUU)
using non-parametric tests (Kruskal Wallis and Mann Whitney). Differences were considered significant
if p < 0.05.
5. Conclusions
Intravitreally administered NMDA in adult albino rats: (i) induces a massive diffuse loss of
Brn3+RGCs, which is evident within the first week and does not progress further; (ii) causes a thinning
of the inner retina at 3 months that further progresses up to 15 months; (iii) triggers a transient
downregulation of melanopsin expression that is evident at 3 days and recovers fully by 14 days, and;
(iv) does not induce m+RGC loss.
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